IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较  

Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma

作　　者：张伟 张振 刘冬 江后洲 梁伟[2] ZHANG Wei;ZHANG Zhen;LIU Dong;JIANG Houzhou;LIANG Wei(Department of Radiotherapy Oncology,Taihe County People′s Hospital,Fuyang 236600;Department of Radiotherapy,Anhui Medical University First Affiliated Hospital,Hefei 230000 China)

机构地区：[1]太和县人民医院肿瘤放疗科,安徽阜阳236000 [2]安徽医科大学第一附属医院肿瘤放疗科,安徽合肥230000

出　　处：《基础医学与临床》2024年第7期1018-1022,共5页Basic and Clinical Medicine

基　　金：安徽省科技重大专项(202103a0720011)。

摘　　要：目的探讨多西他赛+顺铂(DP)及顺铂+5-氟尿嘧啶(PF)方案化疗联合调强适形放射治疗(IMRT)在早期食管鳞癌患者中的不良反应、近期疗效和远期效果。方法选取2021年1月至2022年6月安徽省阜阳市太和县人民医院收治的无远处转移食管鳞癌患者96例为研究对象,将96例患者随机分成观察组48例,对照组48例。对照组采用PF方案加IMRT,观察组给予DP方案化疗联合IMRT。比较两组患者治疗期间不良反应发生情况,以及近远期治疗效果。结果与对照组比较,放射性食管炎、放射性肺炎、血液毒性、胃肠道反应等不良反应发生率差异无统计学意义。近期疗效中,观察组治疗总有效率较对照组高(83.3%vs.62.5%,P<0.05)。远期疗效中,观察组和对照组的总体生存率、1年生存率、3年生存率分别为70.83%和50.00%、79.36%和60.23%、65.10%和35.52%。观察组中位生存时间(34.4个月)较对照组(18.3个月)长(P<0.05)。结论DP方案化疗联合IMRT较PF方案联合IMRT,对于无远处转移食管鳞癌患者,毒副作用未见明显增加,能够有效提高近远期治疗效果,改善疾病预后,可在临床上应用推广。Objective To investigate the adverse reactions,short⁃term and long⁃term effects of DP(docetaxel+cis⁃platin)regimen and PF(cisplatin+5⁃fluorouracil)regimen combined with intensity modulated radiation therapy(IMRT)in patients with distant metastatic esophageal squamous carcinoma.Methods From January 2021 to June 2022,96 patients with non⁃metastatic esophageal squamous carcinoma were randomly divided into 48 cases in Taihe County People′s Hospital of Fuyang City,Anhui province and 48 cases in control group.Which was treated with DP plus IMRT.The observation group was treated with PF plus IMRT.The occurrence of adverse reactions and the effect of both groups were compared.Results Compared with control group,the difference in the incidence of adverse re⁃action was not significant.The total effective rate was higher in the observation group than in that in control group(83.3%vs 62.5%,P<0.05).Overall survival,1⁃year survival,3⁃year survival in observation and in control group were 70.83%vs 50.00%,79.36%vs 60.23%and 65.10%vs 35.52%.Long⁃term outcomes were observed and compared.The median survival time was 34.40 months in the observation group and 18.3 months in control group(P<0.05).Conclusions DP regimen combined with IMRT is more effective than PF regimen combined with IMRT in the treatment of patients with distant metastatic esophageal squamous carcinoma.

关 键 词：食管鳞癌 远处转移 不良反应 近远期效果 同步放化疗 

分 类 号：R735.1[医药卫生—肿瘤]